Skip to content
10-Q

Quarterly Report

Raphael Pharmaceutical Inc. RAPH

0001213900-25-043641

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 19.63M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $50K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $19K
Current Liabilities Q1 2025 · Mar 31, 2025 $827K
Current Liabilities Q1 2025 · Dec 31, 2024 $769K
Current Assets Q1 2025 · Mar 31, 2025 $91K
Current Assets Q1 2025 · Dec 31, 2024 $25K
Total Assets Q1 2025 · Mar 31, 2025 $93K
Total Assets Q1 2025 · Dec 31, 2024 $27K
Shares Diluted Q1 2025 · Mar 31, 2024 18.62M sh
Capex Q1 2025 · Mar 31, 2024 $1K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$172K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$103K
Stockholders Equity Q1 2025 · Dec 31, 2023 $267K
Eps Diluted Q1 2025 · Mar 31, 2024 $0.03
Eps Basic Q1 2025 · Mar 31, 2024 $0.03
Sga Expense Q1 2025 · Mar 31, 2024 $168K
Rd Expense Q1 2025 · Mar 31, 2024 $379K
Net Income Q1 2025 · Mar 31, 2024 −$550K
Operating Income Q1 2025 · Mar 31, 2024 −$547K